Please enable JavaScript or talk to your local administrator to get JavaScript enabled.

Project

Efficacy of BCG Therapy is a Function of Bladder Tumor Immune Microenvironment

Funder: National Cancer Institute

Funding period
USD 392 K
Funding amount
Abstract
DESCRIPTION (provided by applicant): Transitional cell carcinoma is the most common pathologic subtype of bladder cancer and is observed in over 90% of tumors. The significant majority of initially diagnosed tumors are non-muscle invasive lesions (i.e., Ta, T1, and Tis) with subjects often presenting with combinations of two or more of these tumors. The standard-of-care treatment option for these non-muscle invasive bladder cancers are limited but commonly include intravesical administration of live attenuated Bacillus Calmette-Guerin (BCG). However, there is currently no ability at the time of initial diagnosis to identify which of these patients ill respond to this immune modulating standard-of-care treatment. As a consequence, bladder cancer patients are generally treated using a one size fits all approach with only about 60% of treated patients showing no evidence of tumors following BCG immune therapy. Our preliminary immunohistochemical studies using formalin-fixed paraffin embedded initial biopsies (i.e., the only available sample common to all bladder cancer patients from various medical centers/clinics) has provided two insights that suggest the possibility of a novel diagnostic approach to identify BCG therapy-responsive patients. Specifically, the inflammatory/immune responses associated with bladder cancer appear to be Th2-polarized as judged by the preponderance of tumor infiltrating GATA-3+ (Th2) vs. T-bet+ (Th1) T cells and bladder tumors often display evidence of tumor- associated eosinophil infiltration and activation (i.e., degranulation). More importantly, these preliminary insights suggested that assessments of tumor immune responses appear to be positive prognostic indicators of responsiveness to BCG immune therapy. The central hypothesis of this proposal is that the assessments of Th2 immune signature biomarkers in patient biopsies at the time of initial diagnosis will provide needed metrics to identify the 6 out of 10 non-muscle invasive bladder cancer patients responsive to standard-of-care BCG therapy. Our immediate objectives are to translate the immunohistochemical assessments of tumors using antibodies linked with Th2 induced inflammation into an accurate high throughput screen of bladder cancer patients. We will achieve our goals in the short term by completing the following Specific Aim: To demonstrate that the responsiveness of non-muscle invasive bladder cancer to BCG immune therapy correlates with the Th2 character of the tumor immune microenvironment at the time of initial diagnosis (i.e., before the therapeutic decision-making process). In the long term our goal is to translate this validated diagnostic approach into a large prospective patient study designed to test the efficacy of managing bladder cancer patient care with this pathology-based assessment of Th2 biomarkers. Our expectation is that the definition of Th2 immune responses in bladder tumors may also lead to previously untested/novel therapeutic modalities.
Similar projects All >
Sorted by: Start Date
Project list item
Intravesical delivery of an Fc-enhanced CD40 agonist antibody for the treatment of bladder cancer

Bladder Cancer Advocacy Network to Jeffrey Ravetch, David Knorr

USD 300,000
2020 - 2022
Project list item
Epigenetic regulators of subtype plasticity in bladder cancer

Bladder Cancer Advocacy Network to John Robert Christin

USD 1,700
2020 - 2020
Project list item
Characterization of Nectin-4 expression in molecular subtypes of urothelial cancer and mechanisms of resistance to enfortumab vedotin

Bladder Cancer Advocacy Network to Carissa Ellen Chu

USD 1,700
2020 - 2020
Project list item
Recombinant CCL2 as a novel treatment strategy for bladder cancer

Bladder Cancer Advocacy Network to Neelam Mukherjee, Robert Scott Svatek

USD 50,000
2020 - 2021
Project list item
Defining NRF2 induced tumor invasion in bladder cancer

Bladder Cancer Advocacy Network to Yuki Kita, William Youngkwan Kim, Bernard Weissman

USD 50,000
2020 - 2021

System

Categories
  • FOR (ANZSRC)

    1107 Immunology

  • FOR (ANZSRC)

    1112 Oncology and Carcinogenesis

  • RCDC

    Cancer

  • RCDC

    Clinical Research

  • RCDC

    Rare Diseases

  • RCDC

    Urologic Diseases

  • HRCS HC

    Cancer

  • HRCS RAC

    2.1 Biological and endogenous factors

  • HRCS RAC

    4.2 Evaluation of markers and technologies

  • Health Research Areas

    Biomedical

  • Broad Research Areas

    Clinical Medicine and Science